Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients

被引:12
作者
Grieco, A
Castellano, R
Matera, A
Marcoccia, S
Di Rocco, P
Ragazzoni, E
Vecchio, FM
Gasbarrini, G
机构
[1] Univ Cattolica Sacro Cuore, Dept Internal Med & Geriatr, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Pharmacol, I-00168 Rome, Italy
[3] Univ Cattolica Sacro Cuore, Fac Med, Dept Pathol, I-00168 Rome, Italy
关键词
antipyrine clearance; chronic active hepatitis; cirrhosis; hepatocellular carcinoma; liver cancer; liver metastases;
D O I
10.1111/j.1440-1746.1998.tb00668.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Antipyrine metabolism is widely used as an index of the drug-metabolizing reserve of the liver. It is well known that metabolism of this drug is impaired in subjects with acute hepatitis or cirrhosis, but conflicting data have been reported regarding patients with chronic postinfectious hepatitis or liver cancer. We studied conventional liver-function parameters and antipyrine metabolism (antipyrine per o.s. 18 mg/kg) in 518 subjects. One hundred and one patients had liver metastases (various primaries). Based on the number and size of lesions, the hepatic involvement was considered minimal in 47 and massive in 54 (groups B1 and B2, respectively). One hundred and two had chronic active hepatitis (CAH); 51 patients with histological evidence of fibrosis/early cirrhosis and 51 patients were without histological evidence of fibrosis/early cirrhosis. Ninety-two had histologically confirmed cirrhosis (group D), and the remaining 120 had cirrhosis and hepatocellular carcinoma (group E). The control group was composed of 103 subjects with healthy livers (group A). Antipyrine clearance (AP Cl) in CAH patients with fibrosis (0.246 +/- 0.98 ml/min per kg) was similar to that observed in patients with cirrhosis (0.223 +/- 0.148 mL/min per kg), and both values were significantly lower than that found in CAH patients without fibrosis (0.406 +/- 0.159 mL/min per kg, P < 0.01). Antipyrine clearance in patients with liver metastases (0.426 +/- 0.174 mL/min per kg) was similar to that of the healthy group (0.489 +/- 0.210 mL/min per kg). Cirrhotics and cirrhotics with hepatocellular carcinoma (HCC) presented similar degrees of impairment. Antipyrine clearance was positively correlated with serum albumin (r(2) = 0.10, P = 0.01) and prothrombin time (r(2) = 0.129, P < 0.01) in all groups, except those with liver metastases. In patients with CAH, the presence of fibrosis/cirrhosis is associated with impaired antipyrine metabolism. The lack of impairment in groups with liver metastases suggests that the functional hepatic reserve is maintained even in the presence of massive neoplastic invasion.
引用
收藏
页码:460 / 466
页数:7
相关论文
共 50 条
  • [41] Firmicutes and Blautia in gut microbiota lessened in chronic liver diseases and hepatocellular carcinoma patients: a pilot study
    Chen, Tianyou
    Ding, Rongrong
    Chen, Xiaorong
    Lu, Yunfei
    Shi, Jia
    Lu, Ying
    Tang, Bozong
    Zhang, Wensi
    Ye, Chen
    Yuan, Min
    Yang, Zongguo
    BIOENGINEERED, 2021, 12 (01) : 8233 - 8246
  • [42] Relationship of muscle cramps to quality of life and sleep disturbance in patients with chronic liver diseases: A nationwide study
    Iwasa, Motoh
    Karino, Yoshiyasu
    Kawaguchi, Takumi
    Nakanishi, Hiroyuki
    Miyaaki, Hisamitsu
    Shiraki, Makoto
    Nakajima, Tomoaki
    Sawada, Yasuhiko
    Yoshiji, Hitoshi
    Okita, Kiwamu
    Koike, Kazuhiko
    LIVER INTERNATIONAL, 2018, 38 (12) : 2309 - 2316
  • [43] Chronic Liver Diseases as Liver Tumor Precursors
    Lata, Jan
    DIGESTIVE DISEASES, 2010, 28 (4-5) : 596 - 599
  • [44] Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases
    Himoto, Takashi
    Masaki, Tsutomu
    NUTRIENTS, 2020, 12 (07) : 1 - 22
  • [45] Clinical significance of Staphylococcus aureus infection in patients with chronic liver diseases
    Kang, Cheol-In
    Song, Jae-Hoon
    Ko, Kwan Soo
    Chung, Doo Ryeon
    Peck, Kyong Ran
    LIVER INTERNATIONAL, 2010, 30 (09) : 1333 - 1338
  • [46] Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patients
    Hegmar, Hannes
    Wester, Axel
    Aleman, Soo
    Backman, Jens
    Degerman, Erik
    Ekvall, Hakan
    Lund, Katarina
    Lundgren, Asa
    Nasr, Patrik
    Shahnavaz, Afshin
    Vessby, Johan
    Westin, Johan
    Onnerhag, Kristina
    Hagstrom, Hannes
    LIVER INTERNATIONAL, 2024, 44 (07) : 1689 - 1699
  • [47] Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis
    Albuquerque-Souza, Emmanuel
    Sahingur, Sinem E.
    PERIODONTOLOGY 2000, 2022, 89 (01) : 125 - 141
  • [48] Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases
    Nishikawa, Hiroki
    Yoh, Kazunori
    Enomoto, Hirayuki
    Nishimura, Takashi
    Nishiguchi, Shuhei
    Iijima, Hiroko
    IN VIVO, 2021, 35 (04): : 2451 - 2456
  • [49] Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases
    Nishikawa, Hiroki
    Enomoto, Hirayuki
    Yoh, Kazunori
    Iwata, Yoshinori
    Sakai, Yoshiyuki
    Kishino, Kyohei
    Ikeda, Naoto
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Takata, Ryo
    Hasegawa, Kunihiro
    Ishii, Noriko
    Yuri, Yukihisa
    Nishimura, Takashi
    Iijima, Hiroko
    Nishiguchi, Shuhei
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (09)
  • [50] Host Response to the Presence of Helicobacter spp. DNA in the Liver of Patients with Chronic Liver Diseases
    Rybicka, Magda
    Nakonieczna, Joanna
    Stalke, Piotr
    Bielawski, Krzysztof Piotr
    POLISH JOURNAL OF MICROBIOLOGY, 2011, 60 (02) : 175 - 178